Hematopoietic Growth Factors in Oncology

  • Gary H. Lyman
  • David C. Dale

Part of the Cancer Treatment and Research book series (CTAR, volume 157)

Table of contents

  1. Front Matter
    Pages i-xv
  2. Background: Biology, Physiology, and Pharmacology

    1. Front Matter
      Pages 1-1
    2. Gary H. Lyman, David C. Dale
      Pages 3-10
    3. Graham Molineux
      Pages 33-53
    4. Steve Elliott
      Pages 55-74
    5. Ping Wei
      Pages 75-93
  3. The Colony-Stimulating Factors

  4. The Erythroid-Stimulating Agents

  5. The Thrombopoietic Agents

    1. Front Matter
      Pages 249-249
    2. Jason Valent, Charles A. Schiffer
      Pages 251-265
    3. David J. Kuter
      Pages 267-288
    4. James B. Bussel, Mariana P. Pinheiro
      Pages 289-303
  6. Special Considerations

    1. Front Matter
      Pages 305-305
    2. Olga Frankfurt, Martin S. Tallman
      Pages 307-337
    3. Michael Heuser, Arnold Ganser, Dieter Hoelzer
      Pages 339-362
    4. Jose Ortega, Rami Komrokji, Alan F. List
      Pages 363-382
    5. Michelle Shayne, Lodovico Balducci
      Pages 383-402
    6. Adi Eldar-Lissai, Gary H. Lyman
      Pages 403-418
  7. Back Matter
    Pages 419-433

About this book


No area of cancer supportive care better illustrates the advances in our understanding of cellular and molecular biology, genetic engineering and the development of more effective yet often more toxic cancer treatments than that of hematopoietic growth factors. Myelosuppressive agents, with their potential hematopoietic toxicities, remain the mainstay of systemic treatment for both metastatic and early stage cancer. Hematopoietic Growth Factors in Oncology reviews and integrates the major advances in our understanding of the underlying molecular biology and pharmacology of these agents along with the results of well designed and executed randomized controlled trials of the erythroid stimulating agents, the myeloid growth factors and the new thrombopoietic agents, each addressing a major threat associated with bone marrow suppression accompanying cancer treatment. "Hematopoietic growth factors have revolutionized the treatment of patients with a spectrum of cancers and benign bone marrow disorders. This text addresses the mechanism of action and clinical impact of these cytokines. Leading investigators in the field provide and update of current state of knowledge and future challenges." – Steven T. Rosen, M.D. Series Editor


Biology Molecular Genetics Pharmacology

Editors and affiliations

  • Gary H. Lyman
    • 1
  • David C. Dale
    • 2
  1. 1.Department of MedicineDuke University and the Duke ComprehensiDurhamUSA
  2. 2.Health Sciences Center, Department of MedicineUniversity of WashingtonSeattleUSA

Bibliographic information

  • DOI
  • Copyright Information Springer Science+Business Media, LLC 2011
  • Publisher Name Springer, Boston, MA
  • eBook Packages Medicine Medicine (R0)
  • Print ISBN 978-1-4419-7072-5
  • Online ISBN 978-1-4419-7073-2
  • Series Print ISSN 0927-3042
  • Buy this book on publisher's site